全文获取类型
收费全文 | 137132篇 |
免费 | 12570篇 |
国内免费 | 3107篇 |
专业分类
耳鼻咽喉 | 1204篇 |
儿科学 | 9661篇 |
妇产科学 | 3216篇 |
基础医学 | 14018篇 |
口腔科学 | 3193篇 |
临床医学 | 14856篇 |
内科学 | 16527篇 |
皮肤病学 | 1880篇 |
神经病学 | 6366篇 |
特种医学 | 2813篇 |
外国民族医学 | 8篇 |
外科学 | 11580篇 |
综合类 | 19070篇 |
现状与发展 | 14篇 |
一般理论 | 8篇 |
预防医学 | 21998篇 |
眼科学 | 2889篇 |
药学 | 13130篇 |
132篇 | |
中国医学 | 6108篇 |
肿瘤学 | 4138篇 |
出版年
2024年 | 282篇 |
2023年 | 2224篇 |
2022年 | 3223篇 |
2021年 | 5795篇 |
2020年 | 5682篇 |
2019年 | 4980篇 |
2018年 | 4737篇 |
2017年 | 4891篇 |
2016年 | 5143篇 |
2015年 | 4997篇 |
2014年 | 8594篇 |
2013年 | 10884篇 |
2012年 | 8515篇 |
2011年 | 9137篇 |
2010年 | 7044篇 |
2009年 | 6380篇 |
2008年 | 6175篇 |
2007年 | 6367篇 |
2006年 | 5801篇 |
2005年 | 5203篇 |
2004年 | 4353篇 |
2003年 | 3891篇 |
2002年 | 3027篇 |
2001年 | 2774篇 |
2000年 | 2235篇 |
1999年 | 2081篇 |
1998年 | 1853篇 |
1997年 | 1746篇 |
1996年 | 1571篇 |
1995年 | 1453篇 |
1994年 | 1303篇 |
1993年 | 1080篇 |
1992年 | 957篇 |
1991年 | 890篇 |
1990年 | 812篇 |
1989年 | 740篇 |
1988年 | 564篇 |
1987年 | 467篇 |
1986年 | 524篇 |
1985年 | 649篇 |
1984年 | 560篇 |
1983年 | 377篇 |
1982年 | 456篇 |
1981年 | 370篇 |
1980年 | 372篇 |
1979年 | 285篇 |
1978年 | 232篇 |
1977年 | 217篇 |
1976年 | 232篇 |
1975年 | 141篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
71.
72.
73.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献74.
《Vaccine》2016,34(48):5912-5915
Immunochromatography (ICG) is highly used in clinical settings for rotavirus (RV) diagnosis. The specificity of the tests differs by brand type and is not 100%, therefore its use when the prevalence of the disease is low (i.e. in vaccinated children) may result in a proportion of false positive diagnoses.In some areas, vaccine effectiveness studies or surveillance is done using ICG. Our objective was to estimate the validity of ICG test in vaccinated children, and estimate the number of false positive results in the Valencian Region of Spain, where all RV infections are diagnosed using ICG and are not confirmed by PCR.Population based registries were used to identify all results from the RV antigen tests performed between January 2008 and June 2012 in children under 37 months. Hospitalization and vaccination status of the patients were obtained by linking different databases through a unique identification number. The Positive Predictive Value of the ICG test depending on the vaccination status of the child, hospitalization and the rotavirus season was estimated by a Bayesian model of latent classes.Of the 48,833 tests with valid results, 9429 were done in vaccinated children, and of those 3963 (42%) during the rotavirus season. The prevalence of positive results in vaccinated varied from 2.9 to 21.4% of the tests depending on the hospitalization and seasonality. The estimated PPV also varied from 27.1 to 84.6% when stratified by these two parameters. Globally it is calculated that approximately 267 out of the 520 (51.3%) positives in vaccinated children were false positive tests.The large percentage of false positives, due to an excessive number of tests in vaccinated and out of the RV season, if interpreted as vaccine failures, can cause a loss of confidence in the vaccine and lower the estimates of vaccine effectiveness. 相似文献
75.
《Journal of vascular and interventional radiology : JVIR》2020,31(5):760-768.e1
PurposeTo investigate dynamic variables obtained from retrospective computed tomography angiography for ability to predict thoracic endovascular aortic repair (TEVAR) outcomes in patients with complicated type B aortic dissection (cTBAD).Materials and MethodsSeventy-nine patients with cTBAD who received TEVAR from March 2009 to June 2018 were retrospectively enrolled. Relative true lumen area (r-TLA) was computed at the level of tracheal bifurcation every 5% of all R-R intervals. Parameters that reflect the state of intimal motion were evaluated, including difference between maximum and minimum r-TLA (D-TLA) and true lumen collapse. The endpoints comprised early (≤ 30 days) and late (> 30 days) outcomes after intervention.ResultsOverall early mortality rate was 13.9% (11/79), and early adverse events rate was 24.1% (19/79). Patients who received TEVAR within 2 days of symptom onset demonstrated the worst outcomes. A longer time of r-TLA < 25% in 1 cardiac cycle (P = .049) and larger D-TLA (P < .001) were correlated to an increased early death. In addition, D-TLA was an independent predictor of early mortality. Area under the curve of D-TLA was 0.849 (95% confidence interval 0.730–0.967) for predicting early mortality and 0.742 (95% CI 0.611–0.873) for predicting early adverse events. Survival and event-free survival rates during follow-up were decreased in the D-TLA > 21.5% group compared with the D-TLA ≤ 21.5% group (all P < .001).ConclusionsLarger D-TLA is correlated with worse postoperative outcomes and might be a crucial parameter for future risk stratification in patients with cTBAD. 相似文献
76.
77.
室管膜瘤是一种原发于神经上皮的中枢神经系统肿瘤,病变累及脑和脊髓,多发于儿童。基因分型的新分类方法,为室管膜瘤的治疗和预后评估提供了更为可靠的依据。室管膜瘤对辅助治疗的敏感性低是造成患儿预后较差的重要原因之一。该文对近年来儿童室管膜瘤的分型、诊断、治疗策略等进行综述。 相似文献
78.
79.
80.